Ethynylcytidine 产品活性：Ethynylcytidine (ECyD) 是一种核苷类似物，是 RNA 合成 (RNA synthesis) 的有效抑制剂，可抑制 RNA 聚合酶 I，II 和 II。Ethynylcytidine 在多种癌症模型中均具有强大的抗肿瘤活性。Ethynylcytidine 是一种点击化学试剂。它含有 Alkyne 基团，可以和含有 Azide 基团的分子发生铜催化的叠氮-炔环加成反应 (CuAAc)。 产品来源： https://www.medchemexpress.cn/Ethynylcytidine.html 研究领域：Cell Cycle/DNA Damage 作用靶点：DNA/RNA Synthesis | Nucleoside Antimetabolite/Analog In Vitro: The IC50 values of Ethynylcytidine in the five human tumors with 4, 24 and 72 h exposure range from 0.114 to 1.032 μM, 0.015 to 0.067 μM, and 0.008 to 0.058 μM, respectively. These results suggest that the cytotoxicity of Ethynylcytidine tends to become stronger as the exposure time becomes longer. The differences in IC50 values between the 24 and 72 h exposure times are not large, and Ethynylcytidine appeares to show sufficiently potent cytotoxicity at the 24 h exposure time in all 5 human tumors. Even at the 4 h exposure time, Ethynylcytidine clearly shows potent cytotoxicity with IC50 values at submicromolar concentrations in 4 of the 5 human tumors. In Vivo: In both OCUM-2MD3 and LX-1 xenografts, tumor regression is noted and a very potent antitumor effect with an tumor growth inhibition rate (IR) on day 15 of approximately 90% or even higher is observed at the minimum toxic doses of Ethynylcytidine (TAS-106) on all three administration schedules. In particular, administration of Ethynylcytidine at 6 mg/kg once weekly exhibits a marked tumor shrinking effect with an IR of 98% against the LX-1 tumor. While Ethynylcytidine treatment on an either 3 or 5 times weekly schedule has a potent antitumor effect with an IR of approximately 85%, the IR of Ethynylcytidine once weekly is less than 60% and its antitumor effect is rather weak. 相关产品：Covalent Screening Library Plus | Natural Product-like Compound Library | Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Reprogramming Compound Library | Nucleotide Compound Library | Anti-COVID-19 Compound Library | Anti-Lung Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Heterocyclic Compound Library | Anti-Hematopathy Compound Library | Bioactive Compound Library Max | Cycloheximide | Actinomycin D | 5-Fluorouracil | Oxaliplatin | Gemcitabine | Decitabine | 5-Azacytidine | Bleomycin sulfate | Carboplatin | Mitomycin C | Cytarabine | 5-BrdU | Methotrexate | Streptozotocin | Anisomycin | Fludarabine | ART558 | Propidium Iodide | Thymidine | Hydroxyurea | Daunorubicin hydrochloride | Remdesivir | Capecitabine | Adenosine | Brequinar | Urolithin A | Folic acid | CX-5461 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。